Novartis Signs Initial Agreement to Provide Manufacturing Capacity for Pfizer-BioNTech Vaccine
January 29 2021 - 7:22AM
Dow Jones News
By Cecilia Butini
Novartis AG said Friday that it has signed an initial agreement
with BioNTech SE to provide support in the manufacture of the
coronavirus vaccine it is producing with Pfizer Inc.
Under the terms of the agreement, Novartis will take the mRNA
active ingredient from BioNTech, fill it into vials and ship it
back to the German company for distribution.
For this, the Swiss pharmaceutical major will use its aseptic
manufacturing facilities in Stein, Switzerland, it said.
The company plans to start production in the second quarter of
2021, and shipment of the finished product is expected in the third
quarter, it said. This is subject to reaching a final agreement, it
said.
Another European pharmaceutical major, Sanofi SA, recently said
it would support BioNTech in the manufacture of the coronavirus
vaccine under development with Pfizer in a bid to ease the vaccine
shortfall in the European Union.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
January 29, 2021 07:07 ET (12:07 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Sep 2023 to Sep 2024